 |
 |
May 26, 2006
Novartis does R&D on Malaria through a Public Private Partnership (PPP)
Max Oliva, Associate Director of IE's Social Impact Management
The Novartis Institute for Tropical Diseases (NITD) will initiate research on malaria, which together with HIV/AIDS and TB is one of the top three killer diseases in tropical countries.
"With 250 million people infected worldwide and more than one million deaths each year, malaria is one of the most pressing global health issues. This partnership will greatly increase our ability to fight the disease," Dr. Daniel Vasella, Chairman and CEO of Novartis.
The Public Private Partnership is made up of the NITD, the Wellcome Trust, Singapore Economic Development Board (EDB) and Medicines for Malaria Venture (MMV).
Just as an example of the importance of this, according to the EIRIS Risk Briefing on access to medicines for the developing world and the pharmaceutical industry, in the last 25 years of R&D spending, only 1% was for tropical diseases. Only 10% of global health research is on diseases that account for 90% of the world’s disease burden.
Read more about Novartis on Corpooate Citizenship
Read through these great references from the World Heath Organization WHO
Learn more about Malaria
Posted on 26 May 2006 in Corporate Responsibility
Trackback Pings
TrackBack URL for this entry:
http://blogs.ie.edu/cgi-bin/mt-tb.cgi/301
